Stockscreener 앱 받기
10.11
4.65%
0.55
전일 마감가:
$9.56
열려 있는:
$9.61
하루 거래량:
121.64K
Relative Volume:
0.09
시가총액:
$518.00M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.8369
EPS:
-12.08
순현금흐름:
$-257.90M
1주 성능:
+18.82%
1개월 성능:
+1.67%
6개월 성능:
+33.57%
1년 성능:
+286.27%
1일 변동 폭
$9.5801
$10.14
1주일 범위
$7.95
$10.05
52주 변동 폭
$1.42
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.12 | 518.00M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
163.97 | 73.51B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.53 | 43.13B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.30 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.20 | 24.97B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.51 | 14.86B | 15.05B | -883.30M | 1.89B | -0.74 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
Emergent BioSolutions stock leverages NARCAN and vaccine sales for long-term potential - Investing.com Canada
Emergent BioSolutions (EBS) Stock Surge Explained - GuruFocus.com
Why Emergent BioSolutions Stock Blasted Higher Today - MSN
Emergent BioSolutions (NYSE:EBS) Stock Price Up 11.9%What's Next? - MarketBeat
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Emergent BioSolutions (NYSE:EBS) Coverage Initiated at HC Wainwright - MarketBeat
State Street Corp Has $15.96 Million Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Kenvue to Replace Advance Auto Parts in S&P 500; Emergent BioSolutions to be Removed From S&P SmallCap 600 - Marketscreener.com
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine - MSN
Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to Hold - MarketBeat
Emergent BioSolutions receives $50 million contract option from BARDA - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Emergent BioSolutions Inc. Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - Marketscreener.com
Emergent secures $50 million BARDA anthrax vaccine contract By Investing.com - Investing.com Australia
Emergent BioSolutions Receives $50 Million Contract Option from BARDA - citybiz
Emergent secures $50 million BARDA anthrax vaccine contract - Investing.com
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Lands $50M BARDA Contract for FDA-Approved Anthrax Vaccine CYFENDUS - StockTitan
Know Future Outlook of Vaccine Conjugates Market: Key Players Sanofi Pasteur, Emergent BioSolutions - openPR
Oak Hill Advisors LP Invests $9.30 Million in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
War On Drugs 'Has Failed, Completely And Utterly': UN High Commissioner Urges Evidence-Based Solutions - Benzinga
Shigella Infections Market: Projected to Expand Significantly - openPR
Jacobs Levy Equity Management Inc. Invests $1.55 Million in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Emergent to sell Baltimore-Camden production site for $30M - MSN
Point72 Asia Singapore Pte. Ltd. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) lost 9.5% last week but have reaped the benefits of longer-term growth - Simply Wall St
Emergent BioSolutions (EBS) Shares Fall Amidst Institutional Sel - GuruFocus.com
Why Emergent BioSciences Stock Plummeted Today - Yahoo! Voices
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook (SIGA) - Seeking Alpha
Emergent BioSolutions (FRA:ER4) Total Liabilities : €873 Mil (As of Sep. 2024) - GuruFocus.com
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Benzinga
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK
Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com
Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com
Smallpox Treatment Market Is Anticipated To Grow In A Promising - openPR
Russia says African, ex-Soviet countries interested in its mpox vaccine - Reuters
Emergent BioSolutions Inc (EBS) Shares Down 8.02% on Nov 12 - GuruFocus.com
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.23%
0.25%
자본화:
|
볼륨(24시간):